pravastatin / Generic mfg. - LARVOL DELTA

Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort. (PubMed, Front Cardiovasc Med) - "In the moderate-intensity group, rosuvastatin (adjusted HR 1.07, 95% CI 1.01-1.14), pravastatin (HR 1.19, 95% CI 1.02-1.38), and simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin, while fluvastatin and pitavastatin showed no significant differences. In this nationwide secondary prevention cohort, the risk of NODM differed across individual statins despite comparable cardiovascular outcomes. These findings suggest that the diabetogenic effect of statins may be agent-specific rather than a uniform class effect, highlighting the importance of individualized statin selection balancing metabolic and cardiovascular benefits."

Journal • Reimbursement • US reimbursement • Atherosclerosis • Cardiovascular • CNS Disorders • Diabetes • Metabolic Disorders

Syringin Protects Against Doxorubicin-Induced Cardiotoxicity via Apelinr-Dependent Activation of the Nuclear Factor-Erythroid 2-Related Factor 2/Heme Oxygenase-1 Antioxidant Pathway. (PubMed, Phytother Res) - "The cardioprotective effect of Syr was evaluated in a Dox-induced mouse model of cardiotoxicity and in primary cardiomyocytes, with pravastatin (Prv, 10 mg/kg) serving as the positive control in the Syr dose-finding experiment. Our study first demonstrates that Syr protects against Dox-induced cardiotoxicity by restoring the APJ/PI3K/AKT signaling axis, which subsequently enhances the nuclear factor-erythroid 2-related factor 2/heme oxygenase-1 (NRF2/HO-1) antioxidant response and maintains FGF21 homeostasis. These findings identify Syr as a promising natural compound for mitigating chemotherapy-induced cardiotoxicity and highlight the APJ as a novel therapeutic target."

Journal • Cardiovascular • FGF21 • HMOX1

PROBUCOL HALVES ALL-CAUSE DEMENTIA RISK: EVIDENCE FROM A NATIONWIDE COHORT (ADPD 2026) - P2 | "Protective associations were consistent across individual statins, most pronounced versus pravastatin (aOR = 0.31, 95% CI: 0.24–0.38) and pitavastatin (aOR = 0.30, 95% CI: 0.24–0.38). Conclusions Probucol use was associated with significant lower odds of dementia, with robust effects across statin comparators. These findings highlight the translational potential of targeting peripheral amyloid–capillary interactions. Confirmation in the ongoing Probucol in Alzheimer's Study (ACTRN12621000726853) could provide a compelling rationale for scalable and cost-effective adoption of probucol in dementia prevention and treatment."

Alzheimer's Disease • CNS Disorders • Dementia • Inflammation

ATORVASTATIN METABOLITES WITH ANTIOXIDANT ACTIONS LIMIT RAPID OXIDATION OF LIPOPROTEIN(A)-ENRICHED PLASMA MORE EFFECTIVELY THAN OTHER STATINS (ACC 2026) - "We compared the metabolites' effects to other active statins - pitavastatin, rosuvastatin, pravastatin, and simvastatin - on oxidation in plasma samples enriched with Lp(a) and other atherogenic lipoproteins, including small dense LDL (sdLDL). Active metabolites of atorvastatin inhibited oxidation of Lp(a), sdLDL, and LDL enriched plasma compared to other widely used statins as well as in cholesterol-enriched lipid membranes, likely due to free radical scavenging. The potent antioxidant actions of atorvastatin active metabolites may reduce atherogenicity of Lp(a) in patients independent of the production of this atherogenic particle."

Atherosclerosis • Cardiovascular • APOB

Pravastatin Corrects Endothelial Dysfunction in Ex Vivo Uterine Radial Arteries in Preeclampsia. (PubMed, Acta Physiol (Oxf)) - P1 | "Pravastatin restored endothelium-dependent relaxation in uterine radial arteries from PE pregnancies. Data support the therapeutic potential for pravastatin in treating PE, with ongoing trials determining the validity of its use in the clinical setting."

Journal • Preclinical • Gynecology • CAV1

Identification of drug repurposing candidates for amyotrophic lateral sclerosis using electronic health records: a retrospective cohort study. (PubMed, Lancet Digit Health) - "To our knowledge, this analysis is the largest EHR-based study for identifying drug repurposing candidates for ALS. We identified several drugs that warrant further assessment as therapeutic options in ALS, as well as a protein network complex that might serve as a therapeutic target for ALS."

Journal • Retrospective data • Amyotrophic Lateral Sclerosis • CNS Disorders

Statin Induced New-onset Diabetes Mellitus - A Narrative Review. (PubMed, J Community Hosp Intern Med Perspect) - "High-intensity statins like atorvastatin and rosuvastatin carry a greater risk compared to agents such as pravastatin or pitavastatin. Despite the diabetes risk associated with statins, their well-established cardiovascular benefits generally outweigh this concern. This review discusses the current evidence on the association between statin use and NODM, explores potential biological mechanisms, compares the diabetogenic effects of different statins, assess the impact of statin dose and intensity, and outlines implications for clinical practice."

Journal • Review • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity

Estimating the Effect of Pravastatin versus Usual Care Under Full Adherence in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid Lowering Trial (ALLHAT-LLT). (PubMed, Am J Epidemiol) - "Findings were consistent across different definitions of treatment strategies. Our results suggest that the use of pravastatin under full adherence was protective against death, while assignment to pravastatin was not."

Journal • Cardiovascular • Dyslipidemia • Myocardial Infarction

NATIONAL TRENDS IN STATIN AND EZETIMIBE USE AND CARDIOVASCULAR RISK AMONG U.S. ADULTS WITH HYPERLIPIDEMIA: MEPS 2018-2023 (ISPOR 2026) - "Atorvastatin remained the most utilized statin, increasing from 44% in 2018 to 51% in 2023 (p<0.001). Rosuvastatin demonstrated the most rapid growth, doubling from 10% to 21% (p<0.001), while utilization of simvastatin, pravastatin, and lovastatin declined significantly... From 2018 to 2023, lipid-lowering therapy in the U.S. shifted toward higher-intensity statins and greater use of adjunctive treatment strategies, accompanied by measurable improvements in cardiovascular comorbidity burden. These findings highlight progress in guideline-directed lipid management and underscore the value of real-world evidence in informing population-level cardiovascular risk reduction and health policy decision-making."

Clinical • Cardiovascular • Congestive Heart Failure • Dyslipidemia • Heart Failure • Myocardial Infarction

Is Statin Therapy for Elevated Lipid Levels in Patients on mTOR Inhibitors After Heart Transplantation Effective? (ISHLT 2026) - "mTOR inhibitors (mTORi), sirolimus and everolimus, slow progression of CAV in randomized trial though they also increase cholesterol...We aimed to evaluate the efficacy and safety of statin therapy in reducing lipid levels in HTx patients on mTORi.Methods 41 HTx recipients transplanted 2010-2024 were transitioned from pravastatin (low-potency) to high-potency statin (rosuvastatin (≤20mg daily) or atorvastatin (≤40mg)) after initiation of mTORi therapy (half-max statin dose to mitigate interaction with calcineurin inhibitors)...(table)Conclusion Switching patients to high-potency statin therapy effectively lowered lipid levels in heart transplant on mTORi. Statin intensification (within safe dosing parameters) appears safe and well tolerated in this population."

Clinical • Cardiovascular • Transplantation

Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial) (clinicaltrials.gov) - P2 | N=154 | Recruiting | Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Not yet recruiting ➔ Recruiting | Initiation date: Sep 2025 ➔ Jan 2026

Enrollment open • Trial initiation date • Gynecology

Reassessing pravastatin in adult autosomal dominant polycystic kidney disease and potential subgroup benefits. (PubMed, Kidney Int) - No abstract available

Journal • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease

TRADstat: Novel Treatment of Radiation Associated Dysphagia With Statins (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Peter MacCallum Cancer Centre, Australia | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Disorder • Head and Neck Cancer • Oncology • Solid Tumor

Unraveling the complex web: pathogenesis and prevention of gestational diabetes mellitus-related fetal overgrowth. (PubMed, Front Cell Dev Biol) - "Management is evolving to integrate advanced ultrasonic markers, such as fetal abdominal fat layer thickness, and pharmacotherapeutic candidates like metformin or pravastatin. The search utilized a combination of the following keywords and their variants: "gestational diabetes mellitus," "fetal overgrowth," "macrosomia," "placental transport," "insulin resistance," "mTOR," "extracellular vesicles," "microbiome," and "epigenetics." Boolean operators (AND, OR) were applied. Priority was given to human clinical studies, meta-analyses, and large cohort studies, with animal and in vitro experiments included as mechanistic supplements."

Journal • Review • Diabetes • Gestational Diabetes • Metabolic Disorders • AMPK

Long-Term Adherence and Drug Utilisation Patterns Among New Users of Anti-Hyperlipidemic Monotherapy: Development of a Risk Prediction Model. (PubMed, J Eval Clin Pract) - "Simvastatin users demonstrated higher adherence and continuation rates compared to other anti-hyperlipidemic monotherapy users. Factors including older age, female sex, and diabetes medications use were associated with improved adherence. Sensitivity analyses using equivalent dosing regimens yielded consistent findings. These insights into adherence and drug patterns are critical for informing personalised strategies to optimise cardiovascular disease prevention."

Journal • Monotherapy • Retrospective data • Cardiovascular • CNS Disorders • Diabetes • Dyslipidemia • Metabolic Disorders • Movement Disorders • Parkinson's Disease

Pravastatin-Loaded Nanostructured Lipid Carriers: Formulation Optimization and In-Vivo Assessment for Antihyperlipidaemic Effect in Rats. (PubMed, J Drug Target) - "Stability studies confirmed that the formulation was stable under various conditions, and release studies showed sustained release compared with the marketed formulation. These findings suggest that pravastatin-loaded NLCs are promising sustained-release systems for improved management of hyperlipidemia."

Journal • Preclinical • Dyslipidemia

Atorvastatin-Associated Liver Injury: Outcome After Statin Rechallenge. (PubMed, Fundam Clin Pharmacol) - "Our study evidenced frequent recurrence of drug-induced liver injury after atorvastatin rechallenge, whereas subsequent administration of a hydrophilic statin was well tolerated. By combining our data and published cases, we suggest that rosuvastatin or pravastatin carries the lowest risk of recurrence. Study limitations include a focus solely on atorvastatin, a retrospective design, and potential underreporting to the pharmacovigilance system."

Journal • Retrospective data • Hepatology • Liver Failure

EFFECTIVENESS OF STATIN THERAPY FOR ELEVATED LIPID LEVELS IN PATIENTS ON MTOR INHIBITORS AFTER HEART TRANSPLANTATION (WRMC 2026) - "Randomized control trials have demonstrated that one therapeutic strategy to slow the progression of CAV is the use of mTOR inhibitors (mTORi), including sirolimus and everolimus...Methods Used: Between 2010 to 2024, we assessed 41 HTx recipients who were transitioned from pravastatin, a low potency statin, to a high potency statin, specifically rosuvastatin or atorvastatin, after initiating mTORi therapy... Switching patients to high potency statin therapy effectively lowered lipid levels in heart transplant recipients on mTORis. Statin intensification (select dosing) appears safe and well tolerated in this population."

Clinical • Cardiovascular • Dyslipidemia • Metabolic Disorders • Transplantation

Statins halt polycystic liver disease by reprogramming metabolism and normalizing mitochondrial bioenergetics in cystic cholangiocytes. (PubMed, Hepatology) - "Mitochondrial and metabolic dysregulation are central to the pathogenesis of PLD. Targeting cholesterol metabolism with statins represents a promising therapeutic strategy to slow disease progression and reduce cyst burden."

Journal • Fibrosis • Genetic Disorders • Hepatology • Immunology • Metabolic Disorders • Transplantation

Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. (PubMed, Lancet) - "Adverse event data from blinded randomised trials do not support causal relationships between statin therapy and most of the conditions (including cognitive impairment, depression, sleep disturbance, and peripheral neuropathy) listed in product labels as potential undesirable effects. In light of these findings, such labelling and other official sources of health information should be revised so that patients and their doctors can make appropriately informed decisions regarding statin therapy."

Adverse events • Journal • Retrospective data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Diabetes • Metabolic Disorders • Pain • Psychiatry • Sleep Disorder

Repurposing Pravastatin and Metformin for the Treatment and Prevention of Noise-Induced Hidden Hearing Loss in a Mouse Model (ARO 2026) - "ABR and DPOAE thresholds were assessed using two-way ANOVA with Tukey’s multiple comparisons, and wave-I amplitudes with two-way ANOVA followed by Dunnett’s test versus placebo; adjusted p values are reported. After completion with an expanded sample size across sexes, our data demonstrate that metformin plus pravastatin improves early auditory recovery after acoustic trauma. Effects were frequency- and sex-dependent, with combination therapy providing the most consistent protection in males and pravastatin contributing in females. Ongoing histology will clarify synaptic preservation underlying these outcomes and will be presented at February 2026 meeting."

Preclinical • Mood Disorders • Otorhinolaryngology • CTBP2

The many faces of cholesterol in autosomal dominant polycystic kidney disease. (PubMed, Kidney Int) - "The pravastatin clinical trial by Gitomer et al...Emergence of novel lipid-lowering therapies presents new therapeutic opportunities but also risks. Recent studies suggest that cholesterol is important for traffic to and function of polycystins in primary cilia."

Journal • Review • Autosomal Dominant Polycystic Kidney Disease • Cardiovascular • Chronic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease

Ferritin-Based Pravastatin Assembly Augments Mucus Penetration and Ameliorates Acute Lung Injury Via Rho/ROCK Signaling Pathway. (PubMed, Macromol Biosci) - "In vitro and in vivo investigations revealed that Prv@FTn alleviates LPS-induced ALI symptoms through inhibition of the Rho-ROCK I/II signaling pathway. These findings suggest that mucus-penetrating Prv@FTn is a promising Rho/ROCK signaling pathway inhibitor for ALI therapy."

Journal • Acute Lung Injury • Inflammation • Respiratory Diseases

Pravastatin combined with fibrin sealant-embedded BMSCs enhances recovery in steroid-induced avascular necrosis of the femoral head. (PubMed, Sci Rep) - "Group D showed significantly lower serum lipid content and femoral head necrosis than other groups, with HE staining revealing fewer empty lacunae and increased trabecular bone density. Additionally, VEGF expression was markedly elevated in Group D. These findings indicate that BMSCs embedded in biomaterials enhance the therapeutic efficacy for early SANFH, and the combination with pravastatin significantly improves outcomes, suggesting a promising new approach for clinical management of femoral head necrosis."

Journal

Analytical Techniques for the Quantification of Pravastatin and Its Metabolites in Various Matrices: A Comprehensive Review. (PubMed, Biomed Chromatogr) - "The literature demonstrates that liquid chromatography-tandem mass spectrometry and high-performance liquid chromatography remain the most sensitive and reliable platforms for ultratrace bioanalysis, while spectrophotometric and electrochemical methods provide cost-effective alternatives for formulations and higher concentration samples, and capillary electrophoresis offers efficient separation with low solvent use. Future analytical advances should prioritize metabolite-resolved quantification, green extraction strategies, microfluidic and point-of-care designs, and AI-assisted data processing to improve sensitivity, stability assessment, and high-throughput monitoring of PRV in clinical and environmental settings."

Journal • Review • Cardiovascular • Dyslipidemia • Metabolic Disorders